C. Kourousis et al., SALVAGE CHEMOTHERAPY WITH PACLITAXEL, VINORELBINE, AND CISPLATIN (PVC) IN ANTHRACYCLINE-RESISTANT ADVANCED BREAST-CANCER, American journal of clinical oncology, 21(3), 1998, pp. 226-232
The tolerance and the efficacy of the paclitaxel-vinorelbine-cisplatin
combination (PVC regimen) was evaluated in 33 patients with anthracyc
line-resistant stage TV breast cancer, who had disease progression und
er anthracycline- or mitoxantrone-based chemotherapy. Fourteen (42%) a
nd 19 (5S%) patients had primary and secondary resistance to anthracyc
lines, respectively; 70% had visceral metastases. Patients received vi
norelbine (25 mg/m(2)) followed by paclitaxel (135 mg/m(2)) in a 3-hou
r infusion on day 1, and cisplatin (CDDP; 80 mg/m(2)) on day 2, in a 3
-week schedule. A total of 208 chemotherapy courses were administered
(median six courses per patient). Grade 3/4 neutropenia occurred in 13
patients (39%), seven of whom were hospitalized for neutropenic fever
(5% of the courses). There was no toxic death, Grade 4 thrombocytopen
ia occurred in two patients (6%) and grade 3 anemia in three patients
(6%). Grade 2 and 3 neurosensory toxicity occurred in 11 patients (32%
) and two patients (6%), respectively, and grade 3/4 fatigue was obser
ved in four patients (12%). Two (6%) complete and 17 partial responses
(52%) (total, 58%; 95% confidence interval, 42%-75%) were documented.
Stable disease was observed in eight patients (24%) and progression i
n six patients (18%). The median duration of response was 6.5+ months.
The median survival was 15+ months, and the I-year survival was 67%.
In conclusion, PVC regimen is an active and well-tolerated salvage che
motherapy in patients resistant to anthracycline.